Elevation Oncology (NASDAQ:ELEV) Stock Rating Reaffirmed by Wedbush

Elevation Oncology (NASDAQ:ELEV)‘s stock had its “outperform” rating restated by equities research analysts at Wedbush in a note issued to investors on Friday, Benzinga reports. They presently have a $8.00 price objective on the stock. Wedbush’s price target would suggest a potential upside of 116.22% from the stock’s current price.

A number of other equities research analysts also recently weighed in on ELEV. JMP Securities reiterated a “market outperform” rating and issued a $7.00 price target on shares of Elevation Oncology in a research report on Thursday, March 7th. HC Wainwright reiterated a “buy” rating and issued a $6.00 price target on shares of Elevation Oncology in a research report on Tuesday, April 9th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $7.25.

Elevation Oncology Trading Down 3.1 %

Shares of NASDAQ:ELEV opened at $3.70 on Friday. Elevation Oncology has a 12-month low of $0.36 and a 12-month high of $5.89. The stock has a market cap of $202.17 million, a PE ratio of -3.56 and a beta of 1.52. The business has a 50 day moving average of $4.38 and a 200-day moving average of $2.39. The company has a quick ratio of 21.22, a current ratio of 21.22 and a debt-to-equity ratio of 0.55.

Elevation Oncology (NASDAQ:ELEV) last issued its quarterly earnings data on Wednesday, March 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.02. As a group, equities research analysts forecast that Elevation Oncology will post -0.87 earnings per share for the current year.

About Elevation Oncology

Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.